hexane-1,6-disulfonic acid | 54503-01-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: hexane-1,6-disulfonic acid
• 英文别名: Hexan-1,6-disulfonsaeure；Hexamethylendisulfonsaeure；1,6-hexanedisulphonic acid
• CAS: 54503-01-4
• 化学式: C₆H₁₄O₆S₂
• 分子量: 246.306
• InChiKey: FEVYVSQHKFKUEZ-UHFFFAOYSA-N

物化性质

• 熔点：
  78 °C
• 密度：
  1.495±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  126
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  hexane-1,6-disulfonic acid 、 3-甲基苯胺 生成 hexane-1,6-disulfonic acid;3-methylaniline
  参考文献：
  名称：

  KIZLINK J.; RATTAY V., COLLECT. CZECHOSL. CHEM. COMMUN., 52,(1987) N 6, 1514-1519

  摘要：

  DOI：
• 作为产物：
  描述：

  1,6-二溴己烷 生成 hexane-1,6-disulfonic acid
  参考文献：
  名称：

  KIZLINK J.; RATTAY V., COLLECT. CZECHOSL. CHEM. COMMUN., 52,(1987) N 6, 1514-1519

  摘要：

  DOI：

文献信息

• Substituted Sulfonamide Compounds
  申请人：Merla Beatrix

  公开号：US20090186899A1

  公开（公告）日：2009-07-23

  Substituted sulfonamide compounds corresponding to the formula I wherein m, n, p, Q, R 1 , R 2 , R 3 , R 4 , X, Y and Z have the respective meanings defined herein, pharmaceutical compositions containing such compounds, a process for their preparation, and the use of such compounds for the treatment and/or inhibition of pain and other conditions mediated by bradykinin receptor 1 (B1R) and/or bradykinin receptor 2 (B2R).

  对应于公式I的磺胺基替代化合物，其中m、n、p、Q、R1、R2、R3、R4、X、Y和Z具有在此定义的各自含义，包含这种化合物的药物组合物，其制备方法，以及利用这种化合物治疗和/或抑制由激肽激酶受体1（B1R）和/或激肽激酶受体2（B2R）介导的疼痛和其他病症。
• [EN] SUBSTITUTED SULFONAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE SULFONAMIDES SUBSTITUÉS
  申请人：GRUENENTHAL GMBH

  公开号：WO2009090055A1

  公开（公告）日：2009-07-23

  The invention relates to substituted sulfonamide derivatives of the general formula (I'); processes for their preparation, medicaments containing these compounds, and the use of substituted sulfonamide derivatives for the preparation of medicaments

  该发明涉及一般式（I'）的取代磺胺基衍生物，其制备方法，含有这些化合物的药物，以及用于制备药物的取代磺胺基衍生物的用途
• Process for preparing cross-linked polyolefins
  申请人：Borve Kjetil

  公开号：US20050038200A1

  公开（公告）日：2005-02-17

  The present invention refers to a process for preparing cross-linked polyolefins, comprising the steps of adding a diazido compound of the formula (I) N═N═N—X—R—X—N═N=N wherein R represents an aryl, alkyl or aralkyl group having 3 to 20 carbon atoms and X stands for —CO—, —O—CO—SO 2 -, —PO 2 -, —PO 3 —, or -Si (═O)—, and a peroxide compound of the general formula (II) R 1 -X 1 -OO—X 2 —R 2 wherein R 1 and R 2 are the same or different and represent hydrogen, an aryl, alkyl or aralkyl group having 3 to 20 carbon atoms and optionally comprising further peroxide groups, wherein one of R 1 and R 2 can form a ring, and X 1 and X 2 are the same or different and stand for a direct bond, —CO 2 — or —CO— to a polyolefin in powder or pellet form; mixing the product to obtain a mixture; extruding the mixture in an extruder at a temperature above the decomposition temperature of the diazido compound of formula (I) and of the peroxide compound of formula (II).

  本发明涉及一种制备交联聚烯烃的方法，包括以下步骤：向粉末或颗粒状的聚烯烃中加入式（I）的重氮化合物N═N═N—X—R—X—N═N=N，其中R表示具有3至20个碳原子的芳基、烷基或芳基烷基，X表示—CO—、—O—CO—SO2-、—PO2-、—PO3—或-Si（═O）—；向聚烯烃中加入式（II）的过氧化物化合物R1-X1-OO—X2—R2，其中R1和R2相同或不同，表示氢、具有3至20个碳原子的芳基、烷基或芳基烷基，且可包含进一步的过氧化物基团，其中R1和R2之一可以形成环，X1和X2相同或不同，表示直接键、—CO2—或—CO—；混合产品以获得混合物；在挤出机中挤出混合物，在高于式（I）的重氮化合物和式（II）的过氧化物化合物的分解温度的温度下进行。
• Method for treating amyloidosis
  申请人：Kisilevsky Robert

  公开号：US20060167095A1

  公开（公告）日：2006-07-27

  Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

  本发明涉及治疗化合物和方法，用于抑制受试者中的淀粉样沉积，无论其临床设置如何。通过向受试者施用包含阴离子基团和载体分子或其药学上可接受的盐的治疗化合物的有效量，抑制淀粉样沉积，从而抑制淀粉样蛋白与基底膜成分之间的相互作用。首选阴离子基团为磺酸盐和硫酸盐。首选载体分子包括碳水化合物、聚合物、肽、肽衍生物、脂肪族基团、脂环族基团、杂环族基团、芳香族基团及其组合。
• METHOD FOR TREATING AMYLOIDOSIS
  申请人：Kisilevsky Robert

  公开号：US20110002875A1

  公开（公告）日：2011-01-06

  Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

  本文描述了治疗化合物和方法，用于抑制患者体内的淀粉样沉积，无论其临床情况如何。通过向患者施用含有阴离子基团和载体分子的治疗化合物或其药学上可接受的盐的有效量，从而抑制淀粉样沉积，以抑制淀粉样蛋白与基底膜成分之间的相互作用。首选阴离子基团为磺酸盐和硫酸盐。首选载体分子包括碳水化合物、聚合物、肽、肽衍生物、脂肪基团、脂环基团、杂环基团、芳香基团和其组合。